|
|
|||||||||
Dr. Torigian is Assistant Professor of Radiology, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
Dr. Huang is Nuclear Medicine Resident, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
Dr. Houseni is Visiting Scholar in Nuclear Medicine, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
Dr. Alavi is Professor of Radiology; and Director of Research Education, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
This article is available online at http://CAonline.AmCancerSoc.org
To earn free CME credit for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org
Disclosures: Dr. Huang was supported by a training grant through the National Institutes of Health (NIH) (T32-CA093258–03). Dr. Houseni was supported as a visiting scholar by the Ministry of Higher Education of Egypt.
*Please note that these authors have contributed equally to this manuscript.
A multitude of noninvasive, quantitative, functional imaging techniques are currently in use to study tumor physiology, to probe tumor molecular processes, and to study tumor molecules and metabolites in vitro and in vivo using computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and optical imaging (OI). Such techniques can be used in conjunction with structural imaging techniques to detect, diagnose, characterize, or monitor tumors before and after therapeutic intervention. These can also be used to study tumor gene expression, to track cells and therapeutic drugs, to optimize individualized treatment planning for patients with tumors, and to foster new oncologic drug development. In this article, we review the rich variety of functional imaging techniques that are available for these purposes, which are becoming increasingly important for optimal individualized patient treatment in this day and age of "personalized medicine."
This article has been cited by other articles:
![]() |
W. J. McBride, R. M. Sharkey, H. Karacay, C. A. D'Souza, E. A. Rossi, P. Laverman, C.-H. Chang, O. C. Boerman, and D. M. Goldenberg A Novel Method of 18F Radiolabeling for PET J. Nucl. Med., June 1, 2009; 50(6): 991 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Park, J. M. Goo, H. J. Lee, M. A Kim, H.-C. Kim, K. G. Kim, C. H. Lee, and J.-G. Im FN13762 Murine Breast Cancer: Region-by-Region Correlation of First-Pass Perfusion CT Indexes with Histologic Vascular Parameters Radiology, June 1, 2009; 251(3): 721 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. CHOW, Y.-Y. LIN, J.-J. HWANG, H.-E. WANG, Y.-L. TSENG, S.-J. WANG, R.-S. LIU, W.-J. LIN, C.-S. YANG, and G. TING Improvement of Biodistribution and Therapeutic Index via Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/luc Xenografted Mouse Model Anticancer Res, June 1, 2009; 29(6): 2111 - 2120. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E Burdette In vivo imaging of molecular targets and their function in endocrinology J. Mol. Endocrinol., June 1, 2008; 40(6): 253 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Siu, R. Pili, I. Duran, W. A. Messersmith, E. X. Chen, R. Sullivan, M. MacLean, S. King, S. Brown, G. K. Reid, et al. Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors J. Clin. Oncol., April 20, 2008; 26(12): 1940 - 1947. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |